Abstract | AIM: METHODS: HCV1b-derived 44 synthetic peptides were selected based on their binding scores to HLA-A24. Peptide-specific IgG were measured by ELISA. Peptide-specific cytotoxic T-lymphocytes (CTLs) were induced in vitro by repeated peptide-stimulation. RESULTS: We identified three novel candidate peptides of HCV1b proteins containing HLA-A24 binding motifs. Each of them had the ability to induce HLA-A24-restricted and peptide-specific CTL activity, and IgGs specific to each of them were detected in the plasma of HCV1b patients. Among these three peptides, a peptide NS5A 2132-2142 was recognized by both cellular and humoral immunities in the majority of blood samples of patients tested. More importantly, the peptide-stimulated peripheral blood mononuclear cells (PBMCs) showed cytotoxicity against cells cotransfected with NS5A and HLA-A2402 genes in an HLA-restricted manner. This is an additional report to our previous study. CONCLUSION: These findings may provide a new insight into the development of a peptide-based specific immunotherapy for HCV1b-infected patients.
|
Authors | Yukari Takao, Akira Yamada, Shigeru Yutani, Hiroko Takedatsu, Takeharu Ono, Kojyu Etoh, Yi Wang, Susumu Suzuki, Tatsuya Ide, Kunitada Shimotohno, Michio Sata, Kyogo Itoh |
Journal | Hepatology research : the official journal of the Japan Society of Hepatology
(Hepatol Res)
Vol. 37
Issue 3
Pg. 186-95
(Mar 2007)
ISSN: 1386-6346 [Print] Netherlands |
PMID | 17362301
(Publication Type: Journal Article)
|